Aerpio Therapeutics raises $27 million for novel diabetic macular edema drug
This article was originally published in Scrip
Executive Summary
Aerpio Therapeutics, the Cincinnati, Ohio-based company, raised $27 million in a Series A financing round to fund its first-in-class Tie2 receptor activator AKB-9778 through 2014 when the company plans to complete a Phase II clinical trial in the treatment of diabetic macular edema (DME).
You may also be interested in...
Biogen’s Tau Antibody Fails In PSP, But Alzheimer’s Studies Continue
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: